Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178912
What this trial is testing
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Who this might be right for
Phase II Clinical TrialBlinatumomabOlverembatinib+2 more
M.D. Anderson Cancer Center 60